MDA-MB-436 Cells

The MDA-MB-436 cell line is derived from a human breast adenocarcinoma. This cell line is characterized by its triple-negative breast cancer (TNBC) phenotype, lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Such characteristics make it an invaluable model for studying TNBC, a particularly aggressive and difficult-to-treat subtype of breast cancer. The cells exhibit an epithelial morphology and are known for their robust proliferative capacity in vitro. Genetically, MDA-MB-436 cells harbor mutations in key cancer-related genes, including BRCA1 and TP53. The BRCA1 mutation is of particular interest, as it mirrors the genetic alterations found in a subset of hereditary breast cancers. This makes MDA-MB-436 a crucial tool for investigating the mechanisms underlying BRCA1-associated tumorigenesis and for testing potential therapeutic strategies targeting these pathways. Additionally, the cell line has been employed in research focused on chemotherapy resistance, metastasis, and the tumor microenvironment. Researchers working with MDA-MB-436 cells benefit from its well-documented characteristics, allowing for reproducible and reliable experimental outcomes. Studies utilizing this cell line contribute significantly to the understanding of TNBC biology and the development of novel treatments for this challenging cancer subtype. However, care must be taken in experimental design, as the absence of hormone receptors and HER2 expression necessitates alternative approaches compared to other breast cancer models.